Greenwood is a busy lil' guy>>
Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of
Directors
MENLO PARK, Calif., Feb. 3, 2011 /PRNewswire via COMTEX/ -- Corium International,
Inc., a privately-held advanced transdermal drug delivery company, today
announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the
Board of Directors. Dr. Chaudhuri most recently served as President of Valeant
Pharmaceuticals International and previously was President and Chief Executive
Officer of Dow Pharmaceutical Services, Inc. Mr. Greenwood is Executive Vice
President and Chief Financial Officer of Geron Corporation.
"We are excited and honored to welcome two executives of Bhaskar and David's
caliber to Corium's Board of Directors," said Peter Staple, Corium's President
and Chief Executive Officer. "They bring a breadth of experience and
accomplishments that will be invaluable as Corium advances through its next
stages of growth."
With well over 20 years of industry management experience, Dr. Chaudhuri brings
extensive product development and commercialization knowledge to Corium. Before
joining Dow, he served as Vice President of R&D at Penederm, Inc., as General
Manager of the Dermatology Division of Mylan Laboratories, and as Executive Vice
President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan,
where he was responsible for research and development activities as well as
certain of the company's manufacturing operations. As Chief Executive Officer of
Dow, Dr. Chaudhuri led the company through a transition from a contract
development focus to developing an attractive internal product pipeline and the
company's eventual merger with Valeant. Dr. Chaudhuri holds a Doctorate in
Physical Pharmacy, a Master's of Science in Industrial Pharmacy and a Bachelor's
of Science in Pharmacy.
Mr. Greenwood brings substantial expertise in financing pharmaceutical and
biotechnology companies. Before joining Geron, he held various positions in the
investment banking field for over 15 years, including the international
investment bank, J.P. Morgan & Co. Incorporated. He joined Geron in 1995 as the
company's Chief Financial Officer, Treasurer and Secretary and has also served as
the company's Vice President of Corporate Development. Mr. Greenwood is a
director of two of the company's subsidiaries, Geron Bio-Med Limited and TA
Therapeutic Ltd. as well as a director of ViaGen, Inc., an Arizona corporation,
and Clone International, an Australian company. Mr. Greenwood serves on the Board
of Regents of Pacific Lutheran University from which he holds a Bachelor of Arts.
He also has an M.B.A. from Harvard Business School.
Dr. Chaudhuri and Mr. Greenwood join current Corium board members Ron Eastman,
Chairman of the Board of Corium and Managing Director at Essex Woodlands Health
Ventures, Dr. Phyllis Gardner, Partner at Essex Woodlands and Professor of
Medicine at Stanford University, John Kozarich, Chairman and President, ActivX
Biosciences, Inc., Robert Thomas, former CEO of FoxHollow Technologies, Daniel G.
Welch, CEO and President of InterMune, Peter D. Staple, CEO and President of
Corium and Gary W. Cleary, co-founder of Corium. The Company is currently
developing and manufacturing a pipeline of advanced transdermal products
employing its proprietary MicroCor(R) microneedle technology and Corplex(TM)
polymer adhesive technology. Essex Woodlands Health Ventures has been the lead
investor in Corium since 2007.
Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand
Rapids, MI.
About Corium International, Inc.
Corium International, Inc. develops and manufactures products based on its
advanced transdermal drug delivery technologies. The company has developed and
clinically validated two highly differentiated state of the art transdermal
technologies: MicroCor(R) is designed for needle-free delivery of large molecules
such as proteins and peptides, and Corplex(TM) enables the "steady-state"
delivery of small molecules. Corium develops and manufactures both self-funded
proprietary products and products for its partners, which include specialty
pharma, biotech and large, established pharmaceutical companies. Please visit
coriumgroup.com.
Contact Corium International, Inc.
Christina Dickerson
Vice President, Corporate Development
650.298.8257
christina@coriumtech.com |
